NEKTAR THERAPEUTICS Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2010 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Nektar Therapeutics quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2010 to Q4 2023.
  • Nektar Therapeutics Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $855M, a 4.69% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $855M +$38.3M +4.69% Dec 31, 2023 10-K 2024-03-05
Q4 2022 $816M +$30.5M +3.88% Dec 31, 2022 10-K 2024-03-05
Q4 2021 $786M +$116M +17.3% Dec 31, 2021 10-K 2023-02-28
Q4 2020 $670M +$95M +16.5% Dec 31, 2020 10-K 2022-03-01
Q4 2019 $575M +$115M +24.9% Dec 31, 2019 10-K 2021-02-26
Q4 2018 $460M -$35.7M -7.2% Dec 31, 2018 10-K 2020-02-28
Q4 2017 $496M -$169M -25.4% Dec 31, 2017 10-K 2019-03-01
Q4 2016 $666M +$52.5M +8.57% Dec 31, 2016 10-K 2018-03-01
Q4 2015 $613M +$17.3M +2.91% Dec 31, 2015 10-K 2017-03-01
Q4 2014 $596M +$9.65M +1.65% Dec 31, 2014 10-K 2016-03-01
Q4 2013 $586M +$51.8M +9.69% Dec 31, 2013 10-K 2015-02-26
Q4 2012 $534M +$43.6M +8.88% Dec 31, 2012 10-K 2014-02-27
Q4 2011 $491M +$39.9M +8.85% Dec 31, 2011 10-K 2013-03-01
Q4 2010 $451M Dec 31, 2010 10-K 2012-02-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.